An experienced team and a thoughtful, research-driven investment approach create a compelling healthcare offering for investors willing to stomach some volatility. It earns Above Average People and Process ratings.
PGIM Jennison Health Sciences Fund- Class Z PHSZX
- NAV / 1-Day Return 46.54 / +1.62 %
- Total Assets 1.3B
-
Adj. Expense Ratio
0.880%
- Expense Ratio 0.880%
- Distribution Fee Level Average
- Share Class Type Institutional
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.24%
- Turnover 81%
USD | NAV as of Jun 10, 2026 | 1-Day Return as of Jun 10, 2026, 12:10 AM GMT+0
Morningstar’s Analysis PHSZX
Will PHSZX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the PHSZX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of PHSZX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 16.23 | 217M | Healthcare |
UnitedHealth Group Inc | 5.92 | 79M | Healthcare |
Merck & Co Inc | 5.78 | 77M | Healthcare |
Prudential Govt Money Mkt Fd | 5.70 | 76M | Cash and Equivalents |
Thermo Fisher Scientific Inc | 4.59 | 62M | Healthcare |
CVS Health Corp | 3.88 | 52M | Healthcare |
argenx SE ADR | 3.45 | 46M | Healthcare |
Danaher Corp | 3.33 | 45M | Healthcare |
Vertex Pharmaceuticals Inc | 3.33 | 45M | Healthcare |
Regeneron Pharmaceuticals Inc | 3.03 | 41M | Healthcare |
United States